

Available online at www.sciencedirect.com



Tetrahedron

Tetrahedron 64 (2008) 529-535

www.elsevier.com/locate/tet

Regioselective synthesis of sterically encumbered diaryl ethers based on one-pot cyclizations of 4-aryloxy-1,3-bis(trimethylsilyloxy)-1,3-dienes

Muhammad A. Rashid^a, Nasir Rasool^a, Muhammad Adeel^a, Helmut Reinke^a, Anke Spannenberg^b, Christine Fischer^b, Peter Langer^{a,b,*}

^a Institut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany ^b Leibniz-Institut für Katalyse e. V. an der Universität Rostock, Albert-Einstein-Str. 29a, 18059 Rostock, Germany

Leioniz-Institut jur Katatyse e. v. an der Universität Kostock, Albert-Einstein-Str. 29a, 18059 Kostock, German

Received 1 October 2007; received in revised form 26 October 2007; accepted 1 November 2007 Available online 5 November 2007

Abstract

Sterically encumbered diaryl ethers are prepared based on formal [3+3] cyclizations of novel 4-aryloxy-1,3-bis(trimethylsilyloxy)-1,3-dienes. © 2007 Elsevier Ltd. All rights reserved.

1. Introduction

Functionalized diaryl ethers are of pharmacological relevance and occur in a variety of natural products.¹ This includes, for example, geodinhydrate methylester, methyl chloroasterra-te,^{2a,b} 1-desgalloylsanguiin,^{2c} dehydrotrigallic acid,^{2d} epiphor-ellic acid,^{2e} jolkianin,^{2f} remurin A^{2g} and micareic acid (Scheme 1).^{2h} The most important approach to diaryl ethers relies on the Ullmann³ and Buchwald-Hartwig⁴ reaction and on related transformations.⁵ Although these methods are very important, the scope is limited by the availability of the starting materials. In fact, the synthesis of more complex aryl halides or triflates by regioselective functionalizations of arenes is often a difficult task. In addition, the transition metal catalyzed formation of diaryl ethers containing a sterically encumbered ether linkage is often difficult or not possible at all. Some years ago, Chan et al. developed⁶ a convenient approach to salicylates based on the cyclization of 1,3-bis(trimethylsilyloxy)-1,3dienes⁷ with 3-trimethylsilyloxy-2-en-1-ones. We reported the application of this method to the synthesis of a variety of substituted benzene derivatives.⁸ Recently, we reported the synthesis of 5-aryloxysalicylates⁹ and 5-thioaryloxysalicylates

based on reactions of 2-aryloxy- and 2-thioaryloxy-3-trimethylsilyloxy-2-en-1-ones, respectively.¹⁰ Herein, we report, for the first time, the synthesis of 4-aryloxy-1,3-bis(trimethylsilyloxy)-1,3-dienes and their application to the synthesis of diaryl ethers. Noteworthy, the reactions reported herein allow a convenient and regioselective synthesis of sterically encumbered and functionalized diaryl ethers, which are not readily available by other methods.



Scheme 1. Micareic acid.

2. Results and discussion

Ethyl 4-phenoxyacetoacetate (**2a**) was prepared by basemediated reaction of ethyl 4-chloroacetoacetate and phenol (Scheme 2, Table 1). The methyl 4-phenoxyacetoacetates **2b,c** were prepared by Claisen condensation of methyl acetate with the corresponding α -aryloxyacetic chlorides. The silylation of **2a–c** gave the 3-silyloxy-2-en-1-ones **3a–c**. The novel 4-aryloxy-1,3-bis(silyloxy)-1,3-dienes **4a–c** were prepared by

^{*} Corresponding author. Tel.: +49 381 4986410; fax: +49 381 4986412. *E-mail address:* peter.langer@uni-rostock.de (P. Langer).

deprotonation (LDA) of 3a-c at -78 °C and subsequent addition of trimethylchlorosilane. The Me₃SiOTf-catalyzed cyclization of 4-aryloxy-1,3-bis(silyloxy)-1,3-dienes 4a-c with 1,1,3,3-tetramethoxypropane, following our recently reported protocol,¹¹ afforded the 3-aryloxysalicylates 5a-c. During the optimization of cyclization, the concentration and stoichiometry proved to play an important role.



Scheme 2. Synthesis of **5a**–c: (i) NEt₃/KOH, CH₂Cl₂/DMSO, 30 min, 0 °C/ 5 h, 20 °C; (ii) LDA, THF, $-78 \rightarrow 20$ °C, 14 h; (iii) Me₃SiCl, NEt₃, C₆H₆, 20 °C, 72 h; (iv) LDA, THF, $-78 \rightarrow 20$ °C; (v) Me₃SiOTf, CH₂Cl₂, $-78 \rightarrow$ 20 °C, 20 h.

Table 1

Synthesis of diaryl ethers $\mathbf{5a-c}$

2-5	\mathbb{R}^1	R^2	% (2) ^a	% (3) ^a	% (4) ^a	% (5) ^a
a	Н	OEt	60	91	82	45
b	Cl	OMe	30	74	82	46
c	Me	OMe	40	75	84	48

^a Isolated yields.

The TiCl₄-mediated [3+3] cyclization of 1,3-bis(silyloxy)-1,3-dienes $4\mathbf{a}-\mathbf{c}$ with 3-silyloxy-2-en-1-ones $6\mathbf{a}-\mathbf{e}$ afforded the 3-aryloxysalicylates $7\mathbf{a}-\mathbf{g}$ (Scheme 3, Table 2). During the optimization, it proved to be important to carry out the reactions in a highly concentrated solution. In addition, the stoichiometry and temperature are important parameters. The



Scheme 3. Synthesis of 7a-g: (i) TiCl₄, CH₂Cl₂, $-78 \rightarrow 20$ °C, 20 h.

Table 2			
Synthesis of	diaryl	ethers	7a-g

4	6	7	R^1	R^2	R^3	% (7) ^a
a	a	а	Н	OEt	Н	37
a	b	b	Н	OEt	Me	43
a	с	с	Н	OEt	Cl	38
a	d	d	Н	OEt	ArO ^b	30
a	e	e	Н	OEt	PhS	30
b	с	f	Me	OMe	Cl	40
c	b	g	Cl	OMe	Me	40

^a Isolated yields.

^b Ar=3,4-(MeO)₂C₆H₃.

structure of 7g was independently confirmed by X-ray crystal structure analysis (Fig. 1).¹²

The TiCl₄- and TiBr₄-mediated reaction of 1,3-bis(silyloxy)-1,3-diene **4a** with 1,1-diacetylcyclopropane (**8**) afforded the 3-phenoxysalicylates 9a,b containing a remote halide



Figure 1. Ortep plot of 7g.

function (Scheme 4, Table 3). The formation of the products can be explained by means of a domino '[3+3]-cyclization—homo-Michael' reaction.¹³ The structures of **9a** and **9b** were independently confirmed by X-ray crystal structure analyses (Figs. 2 and 3).



Scheme 4. Synthesis of **9a,b**: (i) TiX₄ (X=Cl, Br), CH₂Cl₂, $-78 \rightarrow 20$ °C, 20 h.

The Me₃SiOTf-catalyzed reaction of 1,3-bis(silyloxy)-1,3-diene **4a** with 3-formylchromone **10** afforded the highly functionalized diaryl ether **11** (Scheme 5). The products are

Table 3 Synthesis of 9a , b				
9	Х	% (9) ^a		
a	Cl	40		
b	Br	33		

^a Isolated yields.



Figure 2. Ortep plot of 9a.



Figure 3. Ortep plot of 9b.

formed by a domino 'Michael-retro-Michael-Mukaiyama-Aldol' reaction.¹⁴



Scheme 5. Synthesis of **11**: (i) Me₃SiOTf (0.3 equiv), 20 °C, 10 min; (ii) (1) **4a** (1.3 equiv), CH₂Cl₂, $0 \rightarrow 20$ °C, 12 h; (2) HCl (10%).

The Me₃SiOTf-catalyzed reaction of **4a** with chromone (**12**) afforded product **13**, which was transformed (without purification) into the diaryl ether **14** (Scheme 6). The transformation of **13** into **14** proceeds by a domino 'Michael–retro-Michael–lactonization' reaction.¹⁵ The structure of **14** was independently confirmed by X-ray crystal structure analysis (Fig. 4).

In conclusion, a variety of sterically encumbered diaryl ethers were prepared based on formal [3+3] cyclizations of novel 4-aryloxy-1,3-bis(trimethylsilyloxy)-1,3-dienes. The products are not readily available by other methods.



Scheme 6. Synthesis of **14**: (i) (1) Me₃SiOTf (0.3 equiv), 20 °C, 1 h; (2) **4a** (1.3 equiv), CH₂Cl₂, $0 \rightarrow 20$ °C, 12 h; (3) HCl (10%); (ii) NEt₃ (2.0 equiv), EtOH, 20 °C, 12 h.



Figure 4. Ortep plot of 14.

3. Experimental section

3.1. General comments

All solvents were dried by standard methods and all reactions were carried out under an inert atmosphere. For ¹H and ¹³C NMR spectra the deuterated solvents indicated were used. Mass spectrometric data (MS) were obtained by electron ionization (EI, 70 eV), chemical ionization (CI, H₂O) or electrospray ionization (ESI). For preparative scale chromatography, silica gel (60–200 mesh) was used. Melting points are uncorrected.

3.2. General procedure for the synthesis of aryloxyacetoacetates **2a**-c

Method A: To a mixture of potassium hydroxide (2.0 mmol) in 2 mL of DMSO was dropwise added a solution of phenol (1.0 mmol) in 0.2 mL of DMSO. The mixture was stirred at room temperature for 30 min and then ethyl 4-chloroacetoacetate (1.0 mmol) was added. The mixture was stirred at room temperature overnight and then acidified by addition of hydrochloric acid (4 M). The mixture was extracted with EtOAc and the organic layer was washed with water and then with brine, and dried over Na₂SO₄. The solution was filtered and the solvent of the filtrate was removed under reduced pressure. The crude product was purified by chromatography (silica gel, EtOAc/*n*-heptane). *Method B*: ATHF solution of 2.3 equiv of LDA was prepared by addition of *n*-BuLi (0.93 mL, 2.3 mmol, 2.5 M solution in hexanes) to a THF solution (6 mL) of diisopropylamine (0.32 mL, 2.3 mmol) at 0 °C. After stirring of the solution for 30 min, methyl acetate (0.09 mL, 1.1 mmol) was added at 0 °C. After stirring for 45–60 min, to the solution was added a THF solution (4 mL) of the acid chloride (205 mg, 1.0 mmol) at -78 °C. The temperature was allowed to rise to 20 °C during 5–6 h and the solution was stirred at 20 °C for 8 h. To the solution was added a diluted aqueous solution of HCl and the mixture was extracted with EtOAc (3×200 mL). The organic layers were dried and filtered, the solvent of the filtrate was removed in vacuo, and the residue was purified by chromatography (silica gel, EtOAc/*n*-heptane).

3.2.1. Ethyl 4-phenoxyacetoacetate (2a)

Starting with 4-chloroacetoacetate (14.4 mL, 106.3 mmol), phenol (10.00 g, 106.3 mmol), KOH (11.80 g, 212.7 mmol) and DMSO (212 mL), **2a** was isolated as a colourless oil (14.30 g, 60%); ¹H NMR (300 MHz, CDCl₃): δ =1.29 (t, 3H, *J*=7.0 Hz, CH₃), 3.67 (s, 2H, CH₂), 4.21 (q, 2H, *J*=7.0 Hz, OCH₂), 4.68 (s, 2H, CH₂), 6.85–6.96 (m, 2H, ArH), 7.02– 7.07 (m, 1H, ArH), 7.25–7.34 (m, 2H, ArH); ¹³C NMR (62 MHz, CDCl₃): δ =14.1 (CH₃), 46.5, 62.0, 72.8 (CH₂), 114.6 (2C, CH), 122.4 (CH), 129.9 (2C, CH) 157.4, 166.9, 200.7 (C); IR (neat): $\tilde{\nu}$ =3043 (w), 2983 (m), 2937 (w), 1724 (s), 1599 (s), 1496 (s), 1322 (s), 1244 (s), 1175 (s), 1032 (s), 813 (m), 755 (s), 692 (s), 508 (w); MS (EI, 70 eV): *m/z* (%): 222 (M⁺, 84), 176 (67), 134 (66), 129 (72), 107 (100), 94 (45), 77 (97), 51 (39); HRMS (EI): calcd for C₁₂H₁₄O₄ [M⁺]: 222.08881, found 222.08866.

3.2.2. Methyl 4-(4-chlorophenoxy)acetoacetate (2b)

Starting with 2-(4-chlorophenoxy)acetyl chloride (5.00 g, 24.0 mmol) and methyl acetate (2.14 mL, 26.8 mmol), **2b** was isolated as a colourless solid (2.00 g, 30%), mp 57 °C; ¹H NMR (250 MHz, CDCl₃): δ =3.55 (s, 2H, CH₂), 3.65 (s, 3H, OCH₃), 4.55 (s, 2H, CH₂), 6.74 (d, 2H, *J*=9.1 Hz, ArH), 7.16 (d, 2H, *J*=9.1 Hz, ArH); ¹³C NMR (62 MHz, CDCl₃): δ =45.7 (CH₂), 52.4 (CH₃), 72.6 (CH₂), 115.8 (2C, CH), 126.6 (C), 129.4 (2C, CH) 156.0, 167.1, 199.6 (C); IR (KBr): $\tilde{\nu}$ =3008 (w), 2958 (w), 2931 (w), 1737 (s), 1595 (m), 1493 (s), 1326 (s), 1233 (s), 1158 (s), 1024(s), 986 (m), 823 (s), 636 (m), 512 (m), 495 (w); MS (EI, 70 eV): *m/z* (%): 244 (M⁺, ³⁷Cl, 11), 242 (M⁺, ³⁵Cl, 39), 210 (28), 168 (13), 141 (76), 128 (17), 115 (92), 101 (39), 85.9 (80), 83.9 (100), 59 (23); HRMS (EI): calcd for C₁₁H₁₁ClO₄ [M⁺, ³⁵Cl]: 242.03335, found 242.03404.

3.2.3. Methyl 4-(4-methylphenoxy)acetoacetate (2c)

Starting with 2-(4-methylphenoxy)acetyl chloride (10.00 g, 54.3 mmol), and methyl acetate (4.8 mL, 59.7 mmol), **2c** was isolated as a colourless oil (4.80 g, 40%); ¹H NMR (250 MHz, CDCl₃): δ =2.21 (s, 3H, CH₃), 3.56 (s, 2H, CH₂), 3.64 (s, 3H, OCH₃), 4.52 (s, 2H, CH₂), 6.70 (d, 2H, J=8.6 Hz, ArH), 7.01 (distorted d, 2H, J=8.6 Hz, ArH); ¹³C NMR (62 MHz, CDCl₃): δ =20.3 (CH₃), 46.1 (CH₂), 52.4 (CH₃), 72.6 (CH₂),

114.4 (2C, CH), 130.1 (2C, CH), 131.5, 155.1, 167.3, 200.8 (C); IR (neat): $\tilde{\nu}$ =3030 (w), 2954 (w), 2926 (w), 1731 (s), 1613 (m), 1511 (s), 1437 (m), 1236 (s), 1178 (s), 1066(s), 1039 (m), 817 (s), 510 (w); *m/z* (%): 222 (M⁺, 92), 206 (7), 190 (71), 148 (34), 128 (55), 121 (100), 101 (41), 86 (82), 77 (49), 59 (28); HRMS (EI): calcd for C₁₂H₁₄O₄ [M⁺]: 222.08869, found 222.08866.

3.3. General procedure for the synthesis of diaryl ethers **5***a*–*c*

To a dichloromethane solution (2 mL/mmol of 4) of 4 (1.0 mmol) and of 1,1,3,3-tetramethoxypropane was added TMSOTf (0.1 mmol) at -78 °C. The solution was allowed to warm to 20 °C within 20 h. To the solution was added a saturated aqueous solution of HCl (15 mL). The organic and the aqueous layer were separated and the latter was extracted with dichloromethane (3×15 mL). The combined organic layers were dried (Na₂SO₄), filtered, and the filtrate was concentrated in vacuo and the residue was purified by chromatography.

3.3.1. Ethyl 3-phenoxysalicylate (5a)

Starting with tetramethoxypropane (0.3 mL, 1.8 mmol), 1.3-bis(silvl enol ether) 4a (660 mg, 1.8 mmol) and TMSOTF (0.03 mL, 0.18 mmol), 5a was isolated as a highly viscous colourless oil (210 mg, 45%); ¹H NMR (250 MHz, CDCl₃): $\delta = 1.35$ (t, 3H, J=7.1 Hz, CH₃), 4.35 (q, 2H, J=7.1 Hz, OCH₂), 6. 77 (t, 1H, J=7.9 Hz, ArH), 6.91 (dd, 2H, J=1.1, 8.6 Hz, ArH), 6.99 (m, 1H, ArH), 7.11 (m, 1H, ArH), 7.20 (m, 2H, ArH), 7.62 (dd, 1H, J=1.5, 8.0 Hz, ArH), 10.95 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =14.1 (CH₃), 61.7 (CH₂), 114.2 (C), 117.0 (2C, CH), 118.7, 122.7, 125.7, 126.7 (CH), 129.6 (2C, CH), 144.2, 154.0, 157.6, 170.0 (C); IR (neat): $\tilde{\nu}$ =3072 (w), 2983 (w), 1674 (s), 1585 (s), 1460 (s), 1323 (s), 1253 (s), 1150 (s), 1025 (s), 854 (m), 752 (s), 690 (m), 580 (w), 498 (w); MS (EI, 70 eV): m/z (%): 258 (M⁺, 65), 212 (100), 184 (46), 128 (13), 105 (31), 77 (15), 51 (12); elemental analysis: calcd (%) for C₁₅H₁₄O₄: C 69.76, H 5.46; found: C 69.68, H 5.63.

3.3.2. Methyl 3-(4-chlorophenoxy)salicylate (5b)

Starting with tetramethoxypropane (0.25 mL, 1.5 mmol), 1,3-bis(silyl enol ether) **4b** (582 mg, 1.5 mmol) and TMSOTF (0.027 mL, 0.15 mmol), **5b** was isolated as a highly viscous colourless oil (192 mg, 46%); ¹H NMR (250 MHz, CDCl₃): δ =3.88 (s, 3H, OCH₃), 6.81 (m, 3H, ArH), 7.15 (m, 3H, ArH), 7.61 (dd, 1H, *J*=1.5, 8.0 Hz, ArH), 10.23 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =52.5 (CH₃), 114.1 (C), 118.0 (2C, CH), 118.9, 125.8, 127.0 (CH), 127.6 (C) 129.5 (2C, CH), 143.8, 153.9, 156.3, 170.3 (C); IR (neat): $\tilde{\nu}$ =3099 (w), 2954 (m), 2854 (w), 1680 (s), 1583 (s), 1485 (s), 1329 (s), 1254 (s), 1007 (s), 824 (s), 662 (m), 499 (m), 441 (w); MS (EI, 70 eV): *m*/*z* (%): 280 (M⁺, ³⁷Cl, 24), 278 (M⁺, ³⁵Cl, 71), 246 (100), 218 (26), 211 (50), 155 (9), 139 (34), 107 (20), 75 (9); HRMS (EI): calcd for C₁₄H₁₁ClO₄ [M⁺, ³⁵Cl]: 278.03435, found 278.03404.

3.3.3. Methyl 3-(4-methylphenoxy)salicylate (5c)

Starting with tetramethoxypropane (0.25 mL, 1.5 mmol), 1,3-bis(silyl enol ether) **4c** (554 mg, 1.5 mmol) and TMSOTF (0.027 mL, 0.15 mmol), **5c** was isolated as a highly viscous oil (186 mg, 48%); ¹H NMR (250 MHz, CDCl₃): δ =2.24 (s, 3H, CH₃), 3.89 (s, 3H, OCH₃), 6.72–6.82 (m, 3H, ArH), 7.02–7.09 (m, 3H, ArH), 7.56 (dd, 1H, *J*=1.5, 8.0 Hz, ArH), 10.87 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =20.5, 52.5 (CH₃), 112.8 (C), 116.2 (2C, CH), 117.7, 126.7, 127.5 (CH), 129.2 (2C, CH), 131.3, 143.9, 152.7, 154.1, 169.5 (C); IR (neat): $\tilde{\nu}$ =2955 (w), 2924 (m), 2855 (w), 1680 (s), 1505 (s), 1440 (s), 1329 (s), 1252 (s), 1150 (s), 1006 (m), 815 (m), 718 (w), 501 (w); MS (EI, 70 eV): *m/z* (%): 258 (M⁺, 75), 226 (100), 198 (37), 119 (34), 107 (14), 91 (11), 65 (8), 51 (5); HRMS (EI): calcd for C₁₅H₁₅O₄ [M⁺]: 258.08868, found 258.08866.

3.4. General procedure for the synthesis of diaryl ethers 7*a*-*g*

To a dichloromethane solution (2 mL/mmol of **4**) of **4** (1.0 mmol) and of **6** (1.0 mmol) was added TiCl₄ (1.0 mmol) at -78 °C. The solution was allowed to warm to 20 °C within 20 h. To the solution was added a saturated aqueous solution of NaHCO₃ (15 mL). The organic and the aqueous layer were separated and the latter was extracted with diethyl ether (3×20 mL). The combined organic layers were dried (Na₂SO₄), filtered, and the filtrate was concentrated in vacuo and the residue was purified by chromatography (silica gel, EtOAc/*n*-heptane=1:4).

3.4.1. Ethyl 4,6-dimethyl-3-(phenoxy)salicylate (7a)

Starting with 3-(silyloxy)alk-2-en-1-one **6a** (600 mg, 3.48 mmol), 1,3-bis(silyl enol ether) 4a (1.27 g, 3.48 mmol) and TiCl₄ (0.38 mL, 3.48 mmol), 7a was isolated as a colourless solid (354 mg, 37%), mp 69 °C; ¹H NMR (300 MHz, CDCl₃): $\delta = 1.35$ (t, 3H, J = 7.2 Hz, CH₃), 2.08 (s, 3H, CH₃), 2.46 (s, 3H, CH₃), 4.35 (q, 2H, J=7.0 Hz, OCH₂), 6.54 (s, 1H, ArH), 6.78 (d, 2H, J=8.7 Hz, ArH), 6.90 (t, 1H, J=7.4 Hz, ArH), 7.18 (t, 2H, J=8.1 Hz, ArH), 11.43 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ=14.1, 16.3, 23.7 (CH₃), 61.6 (CH₂), 111.4 (C), 114.6 (2C, CH), 121.6, 124.3 (CH), 129.4 (2C, CH), 137.1, 138.1, 138.9, 155.9, 157.8, 171.2 (C); IR (KBr): *ν*=2988 (m), 2930 (w), 1651 (s), 1590 (m), 1494 (s), 1377 (s), 1300 (s), 1213(s), 1164 (s), 1029 (m), 842 (w), 793 (s), 692 (s), 577 (w), 421 (w); MS (EI, 70 eV): m/z (%): 286 (M⁺, 42), 240 (100), 211 (13), 197 (9), 135 (10), 105 (43), 77 (16); elemental analysis: calcd (%) for C17H18O4 (286.1): C 71.31, H 6.43; found: C 71.18, H 6.66.

3.4.2. Ethyl 4,5,6-trimethyl-3-phenoxysalicylate (7b)

Starting with 3-(siloxy)alk-2-en-1-one **6b** (600 mg, 3.2 mmol), 1,3-bis(silyl enol ether) **4a** (1.18 g, 3.2 mmol) and TiCl₄ (0.35 mL, 3.2 mmol), **7b** was isolated as a colourless solid (414 mg, 43%), mp 75 °C; ¹H NMR (250 MHz, CDCl₃): δ =1.28 (t, 3H, *J*=7.1 Hz, CH₃), 2.02 (s, 3H, CH₃), 2.05 (s, 3H, CH₃), 2.33 (s, 3H, CH₃), 4.30 (q, 2H, *J*=7.0 Hz, OCH₂), 6.71 (dd, 2H, *J*=1.1, 8.6 Hz, ArH), 6.84 (m, 1H, ArH), 7.09–7.15

(m, 2H, ArH), 10.08 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =13.8, 14.1, 15.8, 18.8 (CH₃), 61.7 (CH₂), 113.4 (C), 114.6 (2C, CH), 121.6 (CH), 127.7 (C), 129.5 (2C, CH), 134.3, 136.7, 138.4, 151.6, 158.0, 171.0 (C); IR (KBr): $\tilde{\nu}$ =2992 (w), 2923 (w), 1663 (s), 1591 (s), 1414 (s), 1312 (s), 1251 (s), 1189 (s), 1018 (s), 801 (m), 753 (s), 693 (m), 507 (w), 418 (w); MS (EI, 70 eV): *m/z* (%): 300 (M⁺, 46), 254 (100), 239 (27), 211 (15), 149 (15), 105 (57), 77 (22); elemental analysis: calcd (%) for C₁₈H₂₀O₄ (300.1): C 71.98, H 6.71; found: C 71.66, H 6.77.

3.4.3. Ethyl 4,6-dimethyl-5-chloro-3-phenoxysalicylate (7c)

Starting with 3-(siloxy)alk-2-en-1-one 6c (400 mg, 1.93 mmol), 1,3-bis(silyl enol ether) 4a (707 mg, 1.93 mmol) and TiCl₄ (0.21 mL, 1.93 mmol), 7c was isolated as a colourless solid (234 mg, 38%), mp 47 °C; ¹H NMR (250 MHz, CDCl₃): $\delta = 1.34$ (t, 3H, J=7.1 Hz, CH₃), 2.20 (s, 3H, CH₃), 2.56 (s, 3H, CH₃), 4.38 (q, 2H, J=7.1 Hz, CH₂), 6.75 (d, 2H, J=7.9 Hz, ArH), 6.91 (t, 1H, J=7.3 Hz, ArH), 7.18 (m, 2H, ArH), 10.68 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): $\delta = 13.3, 14.0, 18.6 (CH_3), 61.1 (CH_2), 112.4 (C), 113.0 (2C), 113.0 (2C),$ CH), 120.9 (CH), 125.7 (C), 128.5 (2C, CH), 133.3, 136.0, 138.3, 152.2, 156.5, 169.5 (C); IR (Nujol): $\tilde{\nu}$ =3069 (w), 1664 (s), 1591 (m), 1490 (s), 1401 (s), 1376 (s), 1347 (m), 1246 (s), 1184 (s), 1074 (m), 854 (w), 749 (s), 686 (m), 433 (w); MS (EI, 70 eV): m/z (%): 322 (M⁺, ³⁷Cl, 15), 320 (M⁺, ³⁵Cl, 43), 274 (100), 245 (15), 211 (13), 169 (8), 139 (34), 105 (43), 77 (21); elemental analysis: calcd (%) for $C_{17}H_{17}ClO_4$ (320.08): C 63.65, H 5.34; found: C 63.23, H 5.70.

3.4.4. Ethyl 4,6-dimethyl-3-phenoxy 5-(3,4-dimethoxy-phenoxy)salicylate (7d)

Starting with 3-(siloxy)alk-2-en-1-one 6d (600 mg, 1.83 mmol), 1,3-bis(silyl enol ether) **4a** (671 mg, 1.83 mmol) and TiCl₄ (0.2 mL, 1.83 mmol), 7d was isolated as a highly viscous oil (207 mg, 30%); ¹H NMR (250 MHz, CDCl₃): $\delta = 1.35$ (t, 3H, J = 7.1 Hz, CH₃), 1.95 (s, 3H, CH₃), 2.31 (s, 3H, CH₃), 3.75 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 4.36 (q, 2H, J=7.2 Hz, OCH₂), 6.02 (dd, 1H, J=2.8, 8.6 Hz, ArH), 6.44 (d, 1H, J=2.8 Hz, ArH), 6.64 (d, 1H, J=8.8 Hz, ArH), 6.77-6.81 (m, 2H, ArH), 6.88-6.95 (m, 1H, ArH), 7.16-7.23 (m, 2H, ArH), 11.09 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =10.9, 14.1, 15.1, 55.9, 56.3 (CH₃), 62.0 (CH₂), 100.0, 104.1, 111.9 (CH), 112.0 (C), 114.5 (2C, CH), 121.8 (CH), 129.5 (2C, CH), 130.4, 133.8, 139.4, 143.7, 143.9, 150.1, 152.4, 153.1, 157.7, 171.1 (C); IR (neat): $\tilde{\nu}$ =2999 (w), 2936 (w), 1601 (s), 1508 (s), 1452 (s), 1301 (s), 1261 (s), 1192 (s), 1027 (s), 833 (m), 753 (w), 653 (w), 475 (w); MS (EI, 70 eV): MS (EI, 70 eV): m/z (%): 438.1 (M⁺, 100), 392.1 (87), 377.1 (49), 287.1 (3), 255 (3), 138 (13), 105 (59), 77 (16); HRMS (EI): calcd for C₂₅H₂₆O₇ [M⁺]: 438.16708, found 438.16730.

3.4.5. Ethyl 4,6-dimethyl-3-phenoxy-5-thiophenoxysalicylate (**7e**)

Starting with 3-(siloxy)alk-2-en-1-one **6e** (500 mg, 1.8 mmol), 1,3-bis(silyl enol ether) **4a** (647 mg, 1.8 mmol)

and TiCl₄ (0.19 mL, 1.8 mmol), 7e was isolated as a colourless solid (210 mg, 30%), mp 103 °C; ¹H NMR (300 MHz, CDCl₃): $\delta = 1.34$ (t. 3H, J = 7.0 Hz, CH₃), 2.26 (s. 3H, CH₃), 2.69 (s, 3H, CH₃), 4.37 (q, 2H, J=7.2 Hz, OCH₂), 6.77 (distorted d, 2H, J=7.8 Hz, ArH), 6.86 (dd, 2H, J=1.3, 8.1 Hz, ArH), 6.92-7.02 (m, 2H, ArH), 7.11-7.22 (m, 4H, ArH), 10.99 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =14.1, 16.0, 21.1 (CH₃), 62.2 (CH₂), 114.0 (C), 114.6 (2C, CH), 121.9 (CH), 123.2 (C), 124.6, 124.8 (CH), 125.3 (2C, CH), 129.0 (2C, CH), 129.1 (2C, CH), 137.9, 139.5, 143.2, 144.2, 155.6, 157.5, 170.9 (C); IR (KBr): $\tilde{\nu}$ =3069 (w), 2978 (w), 2928 (m), 2851 (m), 1662 (s), 1599 (s), 1476 (s), 1374 (s), 1244 (s), 1159 (s), 1077 (m), 752 (m), 686 (m), 488 (w); MS (EI, 70 eV): m/z (%): 394 (M⁺, 93), 349 (37), 348 (100), 247 (22), 333 (16), 290 (5), 270 (7), 211 (10), 177 (28), 161 (19), 105 (28), 57 (31); HRMS (EI): calcd for C₂₃H₂₂O₄S [M⁺]: 394.12333, found 394.12343.

3.4.6. Methyl 4,6-dimethyl-5-chloro-3-(4-methylphenoxy)salicylate (**7f**)

Starting with 3-(siloxy)alk-2-en-1-one **6c** (400 mg, 1.9 mmol), 1,3-bis(silyl enol ether) **4b** (711 mg, 1.9 mmol) and TiCl₄ (0.21 mL, 1.93 mmol), **7f** was isolated as a highly viscous oil (248 mg, 40%); ¹H NMR (300 MHz, CDCl₃): δ =2.20 (s, 6H, CH₃), 2.53 (s, 3H, CH₃), 3.88 (s, 3H, CH₃), 6.65 (d, 2H, *J*=8.5 Hz, ArH), 6.97 (d, 2H, *J*=8.8 Hz, ArH), 10.55 (s, 1H, OH); ¹³C NMR (75 MHz, CDCl₃): δ =14.0, 18.6, 19.5, 51.5 (CH₃), 112.3 (C), 113.3 (2C, CH), 125.7 (C), 129.0 (2C, CH), 130.3, 133.0, 136.1, 138.5, 152.1, 154.4, 169.9 (C); IR (neat): $\tilde{\nu}$ =297 (m), 2927 (m), 2871 (w), 1661 (s), 1506 (s), 1444 (s), 1248 (s), 1164 (s), 1040 (m), 846 (m), 707 (w), 612 (w), 503 (w); MS (EI, 70 eV): *m/z* (%): 322 (M⁺, ³⁷Cl, 15), 320 (M⁺, ³⁵Cl, 46), 288 (100), 273 (9), 259 (15), 169 (10), 119 (87), 91 (22), 77 (18); HRMS (EI): calcd for C₁₇H₁₇ClO₄ [M⁺, ³⁵Cl]: 320.08106, found 320.08099.

3.4.7. Methyl 4,5,6-trimethyl-3-(4-chlorophenoxy)salicylate (**7g**)

Starting with 3-(silyloxy)alk-2-en-1-one **6b** (400 mg, 2.1 mmol), 1,3-bis(silyl enol ether) 4c (814 mg, 2.1 mmol) and TiCl₄ (0.23 mL, 2.1 mmol), 7g was isolated as a colourless solid (272 mg, 40%), mp 98 °C; ¹H NMR (300 MHz, CDCl₃): δ =2.01 (s, 3H, CH₃), 2.05 (s, 3H, CH₃), 2.32 (s, 3H, CH₃), 3.82 (s, 3H, CH₃), 6.65 (d, 2H, J=8.9 Hz, ArH), 7.05 (d, 2H, J=8.8 Hz, ArH), 10.23 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =13.8, 15.9, 18.8, 52.3 (CH₃), 113.1 (C), 116.0 (2C, CH), 126.4, 127.8 (C), 129.4 (2C, CH), 134.7, 136.7, 138.3, 151.6, 156.6, 171.6 (C); IR (KBr): $\tilde{\nu}$ =3005(w), 2952 (w), 2926 (w), 1667 (s), 1595 (m), 1485 (s), 1318 (s), 1248 (s), 1298 (s), 1064 (s), 994 (m), 823 (s), 626 (w), 457 (w); MS (EI, 70 eV): m/z (%): 322 (M⁺, ³⁷Cl, 21), 320 (M⁺, ³⁵Cl, 62), 288 (70), 273 (13), 253 (71), 225 (11), 139 (100), 91 (13), 77 (18); elemental analysis: calcd (%) for $C_{17}H_{17}ClO_4$ (320.08): C 63.65, H 5.34; found: C 63.59, H 5.39.

3.4.8. Ethyl 4,6-dimethyl-5-(2-chloroethyl)-3-phenoxysalicylate (**9a**)

Starting 1.1-diacetylclopropane (15) (300 mg, 2.4 mmol). 1,3-bis(silyl enol ether) 4a (1.200 g, 3.3 mmol), TiCl₄ (0.52 mL, 4.8 mmol) and CH₂Cl₂ (110 mL), 9a was isolated as colourless crystals (328 mg, 40%), mp 75 °C; ¹H NMR (250 MHz, CDCl₃): δ=1.34 (t, 3H, J=7.25 Hz, CH₃), 2.14 (s, 3H, CH₃), 2.45 (s, 3H, CH₃), 3.07 (t, 2H, J=6.45 Hz, CH₂), 3.45 (t, 2H, J=7.5 Hz, CH₂), 4.37 (q, 2H, J=6.5 Hz, CH₂), 6.76 (m, 2H, ArH), 6.94 (m, 1H, ArH), 7.76 (m, 2H, ArH), 10.41 (s, 1H, OH); 13 C NMR (62 MHz, CDCl₃): $\delta = 12.4$, 13.1, 17.3 (CH₃), 32.2, 41.1, 60.9 (CH₂), 112.9 (C), 113.6 (2C CH), 120.7 (CH), 126.4 (C), 128.5 (2C CH), 133.9 136.0, 138.0, 151.9, 156.7, 169.8 (C); IR (Nujol): $\tilde{\nu}$ =3381 (w), 2981 (s), 1728 (m), 1669 (m), 1590 (m), 1491 (m), 1301 (m), 1218 (m), 1167 (m), 1036 (m), 788 (w) 750 (m) cm⁻¹; GC–MS (EI, 70 eV): m/z (%): 450 (M⁺, ³⁷Cl, 13), 448 (M⁺, ³⁵Cl, 41), 403 (73), 267 (83), 253 (43), 105 (100), 77 (22); HRMS (EI): calcd for C₁₉H₂₁O₄Cl [M⁺, ³⁵Cl]: 448.11229, found 448.11180.

3.4.9. Ethyl 4,6-dimethyl-5-(2-bromoethyl)-3-phenoxysalicylate (**9b**)

Starting with 1,1-diacetylcyclopropane 15 (300 mg, 2.4 mmol), 1,3-bis(silvl enol ether) 4a (1.20 g, 3.3 mmol), TiBr₄ (873 mg, 2.4 mmol) and CH₂Cl₂ (110 mL), 9b was isolated as colourless crystals (315 mg, 33%), mp 103 °C; ¹H NMR (250 MHz, CDCl₃): $\delta = 1.24$ (t, 3H, J = 7.1 Hz, CH₃), 2.03 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 3.05 (m, 2H, CH₂), 3.22 (m, 2H, CH₂), 4.27 (q, 2H, J=7.1 Hz, CH₂), 6.65 (m, 2H, ArH), 6.83 (m, 1H, ArH), 7.08 (m, 2H, ArH), 10.23 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =11.4, 12.2, 16.3 (CH₃), 27.6, 31.6, 59.9 (CH₂), 111.9 (C), 112.6 (2C CH), 119.5 (CH), 126.5 (C), 127.6 (2C CH), 132.8, 134.9, 137.0, 151.0, 155.7, 168.8 (C); IR (Nujol): $\tilde{\nu}$ =3375 (w), 2978 (s), 1734 (m), 1675 (m), 1590 (m), 1490 (m), 1319 (m), 1219 (m), 1176 (m), 1029 (m), 751 (w) 690 (m) cm⁻¹; GC–MS (EI, 70 eV): m/z (%): 393 (M⁺, ⁸¹Br, 40), 391 (M⁺, ⁷⁹Br, 40), 347 (62), 313 (26), 267 (100), 253 (33), 105 (89), 77 (34); HRMS (EI): calcd for $C_{19}H_{21}O_4Br$ ([(M+1)⁺, ⁷⁹Br]: 392.06177, found 392.06199.

3.4.10. Synthesis of ethyl-5-(2-hydroxy-3-methylbenzoyl)-3-phenoxysalicylate (11)

Me₃SiOTf (0.3 equiv) was added to the 3-formylchromone (1.0 equiv) at 20 °C. After stirring for 10 min, CH₂Cl₂ (8 mL) was added, the solution was cooled to 0 °C and the 1,3-bis-(silyl enol ether) (1.3 equiv) was added. The mixture was stirred at 20 °C for 12 h and was subsequently poured into an aqueous solution of HCl (10%). The organic and the aqueous layer were separated and the latter was extracted with CH₂Cl₂ (3×15 mL). The combined organic layers were washed with brine (25 mL) and dried over Na₂SO₄. The mixture was filtered and the solvent of the filtrate was purified by chromatography (silica gel, EtOAc/*n*-heptane). Starting with 3-formylchromone **10** (411 mg, 2.2 mmol), 1,3-bis(silyl enol ether) **4a** (800 mg, 2.2 mmol) and Me₃SiOTf (0.65 mL, 1.2 mmol), **11** was isolated as a highly viscous oil (300 mg,

35%); ¹H NMR (250 MHz, CDCl₃): δ =1.35 (t, 3H, *J*=7.1 Hz, CH₃), 2.17 (s, 3H, CH₃), 4.39 (q, *J*=7.1 Hz, 2H, CH₂), 6.88 (m, 1H, ArH), 6.94–7.06 (m, 3H, ArH), 7.21–7.30 (m, 4H, ArH), 7.44 (d, *J*=2.1 Hz, 1H, ArH), 8.02 (d, *J*=2.2 Hz, 1H, ArH), 11.45 (s, 1H, OH), 11.49 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): δ =14.1, 20.4 (CH₃), 62.3 (CH₂), 113.8 (C), 116.9 (C), 117.7 (2C, CH), 118.3 (CH), 118.5 (C), 123.6, 126.1, 127.0 (CH), 127.8, 128.6 (C), 129.8 (2C, CH), 132.5, 137.3 (CH), 144.8, 156.8, 156.9, 160.9, 169.6, 198.3 (C); IR (neat): $\tilde{\nu}$ =2982 (w), 2926 (w), 2869 (w), 1678 (s), 1587 (s), 1401 (s), 1376 (s), 1212 (s), 1109 (m), 1028 (s), 827 (m), 788 (s), 691(m), 475 (w) cm⁻¹; GC–MS (EI, 70 eV): *m/z* (%): 392 (M⁺, 100), 347 (43), 258 (31), 212 (44), 184 (13), 135 (54), 105 (24), 77 (27); HRMS (EI) calcd for C₂₃H₂₀O₆ [M⁺]: 392.12554, found 392.12544.

3.4.11. Synthesis of 8-phenoxy-7-hydroxy-6Hbenzo[c]chromen-6-one (14)

Me₃SiOTf (1.3 equiv) was added to the chromone (1.0 equiv) at 20 °C. After stirring for 1 h, CH₂Cl₂ (8 mL) was added, the solution was cooled to 0 °C and the 1,3-bis-(silyl enol ether) (1.3 equiv) was added. The mixture was stirred at 20 °C for 12 h and was subsequently poured into an aqueous solution of HCl (10%). The organic and the aqueous layer were separated and the latter was extracted with CH_2Cl_2 (3×15 mL) and dried over Na₂SO₄. The mixture was filtered and the solvent of the filtrate was removed under reduced pressure to give crude product 13. To an EtOH solution (10 mL) of the latter was added NEt₃ (2.0 equiv) and the mixture was stirred for 12 h at 20 °C. To the solution was added hydrochloric acid (1 M) and then EtOAc. The organic and the aqueous layer were separated and the latter was extracted with EtOAc and dried over Na₂SO₄. The mixture was filtered and the solvent of the filtrate was removed under reduced pressure. The crude product was purified by chromatography (silica gel, EtOAc/n-heptane). Starting with chromone 12 (500 mg, 3.42 mmol), 1,3-bis(silyl enol ether) 4a (1.62 g, 4.4 mmol), Me₃SiOTf (0.8 mL, 4.4 mmol) and NEt₃ (0.95 mL, 6.8 mmol), 14 was isolated as a colourless solid (728 mg, 70%), mp 151 °C; ¹H NMR (250 MHz, CDCl₃): $\delta = 6.93$ (dd, 2H, J = 1.1, 8.6 Hz, ArH), 7.03 (m, 1H, ArH), 7.20-7.28 (m, 4H, ArH), 7.32-7.36 (m, 2H, ArH), 7.43 (distorted d, J=8.6 Hz, 1H, ArH), 7.86 (dd, J=1.8, 8.6 Hz, 1H, ArH), 11.42 (s, 1H, OH); ¹³C NMR (62 MHz, CDCl₃): $\delta = 107.5$ (C), 112.2 (CH), 117.4 (2C, CH), 117.6 (CH), 118.1 (C), 122.9, 123.3, 125.3, 128.5 (CH), 129.7 (2C, CH), 130.2 (CH), 130.5, 143.6, 150.1, 153.9, 157.1, 165.3 (C); IR (KBr): $\tilde{\nu}$ =3138 (w), 3070 (w), 2923 (w), 1684(s), 1586 (s), 1481 (s), 1318 (m), 1220 (s), 1128 (s), 1081 (m), 869 (m), 756 (s), 717 (m), 456 (w) cm⁻¹; GC-MS (EI, 70 eV): m/z (%): 304 (M⁺, 100), 287 (15), 199 (22), 171 (7), 115 (9), 77 (7), 51 (4); HRMS (EI) calcd for $C_{19}H_{12}O_4$ [M⁺]: 304.07316, found 304.07301.

Acknowledgements

Financial support from the state of Pakistan (HEC scholarship for M.A.R. and N.R) is gratefully acknowledged.

References and notes

- Römpp Lexikon Naturstoffe; Steglich, W., Fugmann, B., Lang-Fugmann, S., Eds.; Thieme: Stuttgart, 1997.
- (a) Lee, H. J.; Lee, J. H.; Hwang, B. Y.; Kim, H. S.; Lee, J. J. Antibiot. 2002, 55, 552; (b) Hargreaves, J.; Park, J.-O.; Ghisalberti, E. L.; Sivasithamparam, K.; Skelton, B. W.; White, A. H. J. Nat. Prod. 2002, 65, 7; (c) Hussein, S. A. M.; Ayoub, N. A.; Nawwar, M. A. M. Phytochemistry 2003, 63, 905; (d) Nawwar, M. A. M.; Hussein, S. A. M.; Buddrus, J.; Linscheid, M. Phytochemistry 1994, 35, 1349; (e) Fiedler, P.; Gambaro, V.; Garbarino, J. A.; Quilhot, W. Phytochemistry 1986, 25, 461; (f) Lee, S.-H.; Tanaka, T.; Nonaka, G.-I.; Nishioka, I. Chem. Pharm. Bull. 1991, 39, 630; (g) Yoshida, T.; Ahmed, A. F.; Okuda, T. Chem. Pharm. Bull. 1993, 41, 672; (h) Elix, J. A.; Jones, A. J.; Lajide, L.; Coppins, B. J.; James, P. W. Aust. J. Chem. 1984, 37, 2349.
- For a review, see: (a) Moroz, A. A.; Shvartsberg, M. S. *Russ. Chem. Rev.* 1974, 43, 679; For a recent example, see: (b) Sinisi, R.; Sani, M.; Candiani, G.; Parente, R.; Pecker, F.; Bellosta, S.; Zanda, M. *Tetrahedron Lett.* 2005, 46, 6515 and references cited therein.
- 4. Review: Muci, A. R.; Buchwald, S. R. Top. Curr. Chem. 2002, 219, 131.
- (a) Harkal, S.; Kumar, K.; Michalik, D.; Zapf, A.; Jackstell, R.; Rataboul, F.; Riermeier, T.; Monsees, A.; Beller, M. *Tetrahedron Lett.* 2005, *46*, 3237 and references cited therein; (b) Harkal, S.; Rataboul, F.; Zapf, A.; Fuhrmann, C.; Riermeier, T. H.; Monsees, A.; Beller, M. *Adv. Synth. Catal.* 2004, *346*, 1742.
- (a) Chan, T.-H.; Brownbridge, P. J. Am. Chem. Soc. **1980**, 102, 3534; (b) Brownbridge, P.; Chan, T.-H.; Brook, M. A.; Kang, G. J. Can. J. Chem. **1983**, 61, 688.
- Review of 1,3-bis(trimethylsilyloxy)-1,3-dienes in general: Langer, P. Synthesis 2002, 441.
- 8. Review: Feist, H.; Langer, P. Synthesis 2007, 327.
- Sher, M.; Ahmed, Z.; Rashid, M. A.; Fischer, C.; Spannenberg, A.; Langer, P. *Tetrahedron* 2007, 63, 4929.
- 10. Rashid, M. A.; Reinke, H.; Langer, P. Tetrahedron Lett. 2007, 48, 2321.
- Sher, M.; Ahmed, Z.; Rashid, M. A.; Fischer, C.; Langer, P. J. Org. Chem. 2007, 72, 6284.
- CCDC-662730 (7g), CCDC-660640 (9a), CCDC-660641 (9b) and CCDC-660642 (14) contain all crystallographic details of this publication which are available free of charge at www.ccdc.cam.ac.uk/conts/retrieving .html or can be ordered from the following address: Cambridge Crystallographic Data Centre, 12 Union Road, GB-Cambridge CB21EZ; fax: (+44)1223-336-033; or deposit@ccdc.cam.ac.uk.
- Bose, G.; Nguyen, V. T. H.; Ullah, E.; Lahiri, S.; Görls, H.; Langer, P. J. Org. Chem. 2004, 69, 9128.
- Appel, B.; Rotzoll, S.; Reinke, H.; Langer, P. Eur. J. Org. Chem. 2006, 3638.
- 15. Appel, B.; Saleh, N. N. R.; Langer, P. Chem.-Eur. J. 2006, 12, 1221.